封面
市場調查報告書
商品編碼
1403339

有毒藥物篩檢市場至2030年的預測:按類型、測試類型、技術、最終用戶和地區分類的全球分析

Toxicology Drug Screening Market Forecasts to 2030 - Global Analysis By Type, Test Type, Technology, End User and by Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料,2023年全球有毒藥物篩檢市場規模為 133.4 億美元,預計預測期內年複合成長率為 10.77%,到2030年將達到 273 億美元。

醫學診斷的重要組成部分之一是有毒藥物篩檢,即檢查血液、尿液和頭髮等生物樣本中的藥物及其代謝物。此步驟在許多情況下都是不可或缺的,包括職場檢查、法醫學調查和臨床評估。此外,有毒藥物篩檢可以透過使用層析法-質譜法和免疫分析等先進的分析技術來檢測各種物質,包括毒素、非法藥物和免疫測量藥。

根據IFPMA2021年報告,生物製藥產業的年度研發支出是航太和國防工業的7.3倍,是化學工業的6.5倍,是軟體和電腦服務產業的1.5倍。

藥物濫用增加

推動有毒藥物篩檢市場的主要因素之一是藥物濫用發生率的上升,包括傳統藥物和新開發的合成物質。此外,比以往任何時候都更需要有效的篩檢方法來識別和治療藥物濫用,特別是考慮到鴉片類藥物危機。為了應對這一促進因素,市場開發了能夠檢測多種物質的新型篩檢技術,包括對現有篩選技術構成挑戰的新合成藥物。

新物質鑑定困難

主要障礙之一是設計藥物和新型精神活性物質(NPS)的快速崛起,這使得傳統的毒性篩檢技術不斷複雜化。隨著藥物濫用領域的變化,篩檢分析很難跟上非法藥物配方的動態變化。此外,為了因應新化合物的檢測,需要透過不斷的研發來提升篩檢能力。

尖端篩檢技術的開發

開發更先進、更全面的篩檢技術潛力巨大。質譜和層析法等分析技術的持續研究和創新提高靈敏度和特異性,能夠檢測更廣泛的物質。此外,投資尖端技術將使相關人員能夠更準確、更有效地滿足不斷變化的毒理學篩檢需求。

設計藥物的快速發展

設計藥物和新型精神活性物質(NPS)的開發對現有的毒理學篩檢技術構成了嚴重威脅。這些物質迅速發展,使得利用篩檢分析來識別和檢測新化合物變得困難。此外,這可能導致假陰性結果並降低藥物測試的有效性。

COVID-19 的影響:

COVID-19 大流行對有毒藥物篩檢市場產生了重大影響,並改變了醫療保健優先事項和程序。由於重點解決突發公共衛生事件,藥物檢測項目和其他常規醫療保健服務已暫停。毒理學測試,特別是對重要工作人員和急診室的毒理學測試,仍然是必要的,但大流行給樣本收集、實驗室操作和一般物流帶來了挑戰。此外,投資尖端毒理學技術的決定也受到大流行期間預算限制和經濟不確定性的影響。

預測期內心血管疾病藥物篩檢領域可望成為最大

心血管疾病藥物篩檢領域預計將佔最大佔有率。全世界發病和死亡的主要原因是心血管疾病,包括血脂異常症和高血壓等疾病。因此,藥物研發最重要的方面之一就是針對心血管疾病的藥物篩檢。此外,確定針對心臟和血管健康風險因素(如血壓、膽固醇和凝血因子)的藥物和治療方法是心血管藥物篩檢市場的核心。

診斷實驗室產業預計在預測期內年複合成長率最高。

診斷實驗室領域預計在預測期內年複合成長率最高。診斷實驗室提供各種用於疾病診斷和監測的測試,使其成為醫療保健過程的重要組成部分。此外,慢性病盛行率的上升和診斷技術的進步增加了對先進檢測服務的需求。由於診斷實驗室在精準和個人化醫療中的關鍵作用以及與製藥公司和醫療保健提供者的合作夥伴關係,診斷實驗室在該市場的持續成長中處於有利地位。

佔比最大的地區:

預計北美將佔據最大佔有率。促成這一優勢的因素有很多,包括對研發的大量投資,完善的診斷實驗室網路,慢性病的高盛行率以及先進的醫療基礎設施。尤其美國,由於其強大的醫療保健系統和診斷技術的不斷進步,成為推動市場成長的主要因素。此外,北美繼續主導診斷實驗室市場,部分原因是其強調個體化醫療保健和精準醫療。

年複合成長率最高的地區:

由於對先進診斷服務的需求不斷成長、醫療保健意識不斷提高以及感染疾病和慢性病的流行等因素,診斷測試市場預計將以亞太地區(APAC)最高的年複合成長率成長。隨著診斷技術的顯著進步,中國、印度和日本等國家正大力投資醫療基礎設施。此外,該地區診斷實驗室市場的強勁成長也歸功於亞太國家對預防醫學的重視和精準醫學的採用。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一:

  • 公司簡介
    • 其他市場參與者的綜合分析(最多3家公司)
    • 主要企業SWOT分析(最多3家公司)
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率(註:基於可行性檢查)
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病(COVID-19)的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球有毒藥物篩檢市場:依類型

  • 心血管疾病藥物篩檢
  • 減肥藥篩檢
  • 糖尿病藥物篩檢
  • 其他類型

第6章 全球有毒藥物篩檢市場:依測試類型

  • 急性全身毒性
  • 經皮毒性
  • 致癌性
  • 眼毒性
  • 遺傳毒性
  • 神經毒性
  • 器官特異性毒性
  • 其他測試類型

第7章 全球有毒藥物篩檢市場:依技術分類

  • 高通量篩檢
  • 基因組學
  • 轉錄組學
  • 毒理基因組學
  • 分子篩檢
  • 其他技術

第8章 全球有毒藥物篩檢市場:依最終用戶分類

  • 醫院與創傷中心
  • 法醫學研究所
  • 診斷實驗室
  • 復健中心
  • 製藥和生物技術公司
  • 其他最終用戶

第9章 全球有毒藥物篩檢市場:依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Covance, Inc.
  • Agilent Technologies Inc.
  • Enzo Life Sciences Inc.
  • Danaher
  • Alere, Inc.
  • BioReliance, Inc.
  • Eurofins Scientific
  • Bio-Rad Laboratories Inc.
  • Promega Corporation
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International Inc.
Product Code: SMRC24564

According to Stratistics MRC, the Global Toxicology Drug Screening Market is accounted for $13.34 billion in 2023 and is expected to reach $27.30 billion by 2030 growing at a CAGR of 10.77% during the forecast period. One essential part of medical diagnostics is toxicology drug screening, which looks for drugs or their metabolites in biological samples like blood, urine, or hair. In a number of contexts, such as workplace testing, forensic investigations, and clinical evaluations, this procedure is essential. Moreover, toxicology drug screening can detect a variety of substances, including toxins, illicit drugs, and prescription medications, by using advanced analytical techniques like chromatography-mass spectrometry and immunoassays.

According to the IFPMA's 2021 report, the annual R&D spending by the biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Growing number of cases of substance abuse

One of the main factors propelling the toxicology drug screening market is the rising incidence of substance abuse, which includes both conventional drugs and newly developed synthetic substances. Additionally, particularly in light of the opioid crisis, there is a greater need than ever for efficient screening methods that identifies and treats drug abuse. In response to this driver, the market has developed novel testing methodologies that can detect a wide range of substances, including new designer drugs that present challenges to established screening techniques.

Restraint:

Difficulties in identifying novel substances

The quick rise of designer drugs and new psychoactive substances (NPS), which continuously complicate conventional toxicology screening techniques, is one major barrier. As the world of substance abuse changes, screening assays find it challenging to keep up with the dynamic nature of illicit drug formulations. Furthermore, enhancing screening capabilities through ongoing research and development is necessary to adjust to the detection of novel compounds.

Opportunity:

Development of cutting-edge screening technologies

The development of more sophisticated and all-encompassing screening technologies has a great deal of potential. Improved sensitivity, specificity, and the capacity to detect a wider variety of substances can result from ongoing research and innovation in analytical techniques like mass spectrometry and chromatography. Moreover, putting money into state-of-the-art technologies puts stakeholders in a position to more accurately and efficiently handle the changing demands of toxicology screening.

Threat:

Designer drugs quick evolution

The development of designer drugs and novel psychoactive substances (NPS) presents a serious threat to established toxicology screening techniques. These substances are evolving quickly, which makes it difficult for screening assays to identify and detect new compounds. Additionally, this could result in false negative results and reduce the effectiveness of drug testing.

COVID-19 Impact:

The COVID-19 pandemic has had a profound effect on the market for toxicology drug screening, changing healthcare priorities and procedures. Drug testing programs and other regular healthcare services have been disrupted as a result of the focus on solving the public health emergency. Although there was still a need for toxicology screening, especially for critical workers and in emergency rooms, the pandemic created difficulties for sample collection, laboratory operations, and general logistics. Furthermore, decisions to invest in cutting-edge toxicology technologies were influenced by budgetary constraints and economic uncertainties during the pandemic.

The Cardiovascular Disease Drug Screening segment is expected to be the largest during the forecast period

The cardiovascular disease drug screening segment is projected to hold the largest share. The world's leading causes of morbidity and mortality are cardiovascular diseases, which include ailments like dyslipidemia and hypertension. Thus, one of the most important aspects of pharmaceutical research and development is drug screening for cardiovascular diseases. Moreover, the identification of drugs and treatments that target heart and vascular health risk factors, such as blood pressure, cholesterol, and clotting factors, is central to the cardiovascular drug screening market.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

Over the course of the forecast period, the diagnostic laboratories segment is expected to have the highest CAGR. Diagnostic laboratories offer a wide variety of tests for the diagnosis and monitoring of diseases, which makes them essential to the healthcare process. Additionally, the need for advanced testing services has increased due to the rising prevalence of chronic conditions and the development of diagnostic technologies. Due to their crucial role in precision and personalized medicine, as well as their partnerships with pharmaceutical companies and healthcare providers, diagnostic laboratories are well-positioned for continued growth in this market.

Region with largest share:

North America is expected to hold the largest share. Many factors contribute to this prominence, including substantial investments in research and development, a well-established network of diagnostic laboratories, a high prevalence of chronic diseases, and an advanced healthcare infrastructure. The United States, in particular, is a major factor driving market growth because of its strong healthcare system and ongoing advancements in diagnostic technology. Furthermore, North America continues to dominate the market for diagnostic laboratories, in part because of the region's emphasis on personalized healthcare and precision medicine.

Region with highest CAGR:

The diagnostic laboratories market is expected to grow at the highest CAGR in the Asia-Pacific (APAC) region, due to factors such as growing demand for advanced diagnostic services, rising healthcare awareness, and the prevalence of infectious and chronic diseases. Alongside significant advancements in diagnostic technologies, nations like China, India, and Japan are investing heavily in their healthcare infrastructure. Moreover, the region's strong growth in the diagnostic laboratory market is also attributed to the emphasis on preventive healthcare and the adoption of precision medicine practices in several APAC countries.

Key players in the market:

Some of the key players in Toxicology Drug Screening market include Covance, Inc., Agilent Technologies Inc., Enzo Life Sciences Inc., Danaher, Alere, Inc., BioReliance, Inc., Eurofins Scientific, Bio-Rad Laboratories Inc., Promega Corporation, GE Healthcare, Thermo Fisher Scientific Inc and Charles River Laboratories International Inc.

Key Developments:

In November 2023, Danaher will acquire all of the outstanding shares of Abcam for $24 per share in cash, for a total enterprise value of approximately $5.7bn including assumed indebtedness and net of acquired cash.

In September 2023, Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

In July 2023, Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Types Covered:

  • Cardiovascular Disease Drug Screening
  • Obesity Drug Screening
  • Diabetes Drug Screening
  • Other Types

Test Types Covered:

  • Acute Systemic Toxicity
  • Dermal Toxicity
  • Carcinogenicity
  • Ocular Toxicity
  • Genotoxicity
  • Neurotoxicity
  • Organ-Specific Toxicity
  • Other Test Types

Technologies Covered:

  • High-Throughput Screening
  • Genomics
  • Transcriptomics
  • Toxicogenomics
  • Molecular Screening
  • Other Technologies

End Users Covered:

  • Hospitals and Trauma Centers
  • Forensic Laboratories
  • Diagnostic Laboratories
  • Rehabilitation Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Toxicology Drug Screening Market, By Type

  • 5.1 Introduction
  • 5.2 Cardiovascular Disease Drug Screening
  • 5.3 Obesity Drug Screening
  • 5.4 Diabetes Drug Screening
  • 5.5 Other Types

6 Global Toxicology Drug Screening Market, By Test Type

  • 6.1 Introduction
  • 6.2 Acute Systemic Toxicity
  • 6.3 Dermal Toxicity
  • 6.4 Carcinogenicity
  • 6.5 Ocular Toxicity
  • 6.6 Genotoxicity
  • 6.7 Neurotoxicity
  • 6.8 Organ-Specific Toxicity
  • 6.9 Other Test Types

7 Global Toxicology Drug Screening Market, By Technology

  • 7.1 Introduction
  • 7.2 High-Throughput Screening
  • 7.3 Genomics
  • 7.4 Transcriptomics
  • 7.5 Toxicogenomics
  • 7.6 Molecular Screening
  • 7.7 Other Technologies

8 Global Toxicology Drug Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Trauma Centers
  • 8.3 Forensic Laboratories
  • 8.4 Diagnostic Laboratories
  • 8.5 Rehabilitation Centers
  • 8.6 Pharmaceutical & Biotechnology Companies
  • 8.7 Other End Users

9 Global Toxicology Drug Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Covance, Inc.
  • 11.2 Agilent Technologies Inc.
  • 11.3 Enzo Life Sciences Inc.
  • 11.4 Danaher
  • 11.5 Alere, Inc.
  • 11.6 BioReliance, Inc.
  • 11.7 Eurofins Scientific
  • 11.8 Bio-Rad Laboratories Inc.
  • 11.9 Promega Corporation
  • 11.10 GE Healthcare
  • 11.11 Thermo Fisher Scientific Inc.
  • 11.12 Charles River Laboratories International Inc.

List of Tables

  • Table 1 Global Toxicology Drug Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Toxicology Drug Screening Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Toxicology Drug Screening Market Outlook, By Cardiovascular Disease Drug Screening (2021-2030) ($MN)
  • Table 4 Global Toxicology Drug Screening Market Outlook, By Obesity Drug Screening (2021-2030) ($MN)
  • Table 5 Global Toxicology Drug Screening Market Outlook, By Diabetes Drug Screening (2021-2030) ($MN)
  • Table 6 Global Toxicology Drug Screening Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Toxicology Drug Screening Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 8 Global Toxicology Drug Screening Market Outlook, By Acute Systemic Toxicity (2021-2030) ($MN)
  • Table 9 Global Toxicology Drug Screening Market Outlook, By Dermal Toxicity (2021-2030) ($MN)
  • Table 10 Global Toxicology Drug Screening Market Outlook, By Carcinogenicity (2021-2030) ($MN)
  • Table 11 Global Toxicology Drug Screening Market Outlook, By Ocular Toxicity (2021-2030) ($MN)
  • Table 12 Global Toxicology Drug Screening Market Outlook, By Genotoxicity (2021-2030) ($MN)
  • Table 13 Global Toxicology Drug Screening Market Outlook, By Neurotoxicity (2021-2030) ($MN)
  • Table 14 Global Toxicology Drug Screening Market Outlook, By Organ-Specific Toxicity (2021-2030) ($MN)
  • Table 15 Global Toxicology Drug Screening Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 16 Global Toxicology Drug Screening Market Outlook, By Technology (2021-2030) ($MN)
  • Table 17 Global Toxicology Drug Screening Market Outlook, By High-Throughput Screening (2021-2030) ($MN)
  • Table 18 Global Toxicology Drug Screening Market Outlook, By Genomics (2021-2030) ($MN)
  • Table 19 Global Toxicology Drug Screening Market Outlook, By Transcriptomics (2021-2030) ($MN)
  • Table 20 Global Toxicology Drug Screening Market Outlook, By Toxicogenomics (2021-2030) ($MN)
  • Table 21 Global Toxicology Drug Screening Market Outlook, By Molecular Screening (2021-2030) ($MN)
  • Table 22 Global Toxicology Drug Screening Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 23 Global Toxicology Drug Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Toxicology Drug Screening Market Outlook, By Hospitals and Trauma Centers (2021-2030) ($MN)
  • Table 25 Global Toxicology Drug Screening Market Outlook, By Forensic Laboratories (2021-2030) ($MN)
  • Table 26 Global Toxicology Drug Screening Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 27 Global Toxicology Drug Screening Market Outlook, By Rehabilitation Centers (2021-2030) ($MN)
  • Table 28 Global Toxicology Drug Screening Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 29 Global Toxicology Drug Screening Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.